Heart and kidney problems in HFpEF (heart failure with preserved ejection fraction)
Human Cardiorenal Syndrome
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-11309578
Testing ways to tell apart and better treat two kinds of HFpEF—one linked to chronic kidney disease and fluid overload, and one that mainly causes breathlessness with exercise.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11309578 on ClinicalTrials.gov |
What this research studies
You would join a project looking at two common types of HFpEF: people whose symptoms come from fluid overload related to chronic kidney disease, and people whose main problem is shortness of breath during exercise. Researchers will compare blood tests, heart and blood‑vessel function, exercise testing, and other measurements to find biological differences between these groups. The team aims to find blood markers that can reliably separate the two types and to try treatments tailored to the underlying cause, including approaches that affect natriuretic peptides and blood‑pressure pathways. Participation may involve clinic visits, blood draws, imaging, and exercise tests, and could include medication testing at Mayo Clinic or collaborating sites.
Who could benefit from this research
Good fit: Adults with heart failure with preserved ejection fraction, especially those with chronic kidney disease and volume overload or those who get short of breath with exercise, would be ideal candidates.
Not a fit: People with heart failure with reduced ejection fraction (reduced EF) or heart conditions unrelated to HFpEF are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, this work could lead to treatments matched to a person’s HFpEF subtype, improving symptoms and reducing hospital visits.
How similar studies have performed: Some drugs help people with reduced EF, but trials like PARAGON did not show clear benefit in HFpEF, so targeted phenotyping and subtype‑specific therapy is a relatively new and needed approach.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHEN, HORNG H — MAYO CLINIC ROCHESTER
- Study coordinator: CHEN, HORNG H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.